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Abstract
Background: There are no proven therapies that modify the structural changes associated with osteoarthritis (OA).
Preclinical data suggests that intra-articular recombinant human BMP-7 (bone morphogenetic protein-7) has
reparative effects on cartilage, as well as on symptoms of joint pain. The objective of this study was to determine
the safety and tolerability as well as dose-limiting toxicity and maximal tolerated dose of intra-articular BMP-7. The
secondary objectives were to determine the effect on symptomatic responses through 24 weeks.
Methods: This was a Phase 1, double-blind, randomized, multi-center, placebo-controlled, single-dose escalation
safety study consisting of 4 dosing cohorts in participants with knee OA. Each cohort was to consist of 8 treated
participants, with treatment allocation in a 3:1 active (intra-articular BMP-7) to placebo ratio. Eligible participants
were persons with symptomatic radiographic knee OA over the age of 40. The primary objective of this study was
to determine the safety and tolerability of BMP-7 including laboratory assessments, immunogenicity data and
radiographic assessments. Secondary objectives were to determine the proportion of participants with a 20%, 50%,
and 70% improvement in the WOMAC pain and function subscales at 4, 8, 12, and 24 weeks. Other secondary
outcomes included the change from baseline to 4, 8, 12, and 24 weeks for the OARSI responder criteria.
Results: The mean age of participants was 60 years and 73% were female. All 33 participants who were enrolled
completed the study and most adverse events were mild or moderate and were similar in placebo and BMP-7
groups. The 1 mg BMP-7 group showed a higher frequency of injection site pain and there was no ectopic bone
formation seen on plain x-rays. By week 12, most participants in both the BMP-7 and placebo groups experienced
a 20% improvement in pain and overall the BMP-7 group was similar to placebo with regard to this measurement.
In the participants who received 0.1 mg and 0.3 mg BMP-7, there was a trend toward greater symptomatic
improvement than placebo. The other secondary endpoints showed similar trends including the OARSI responder
criteria for which the BMP-7 groups had more responders than placebo.
Conclusions: There was no dose limiting toxicity identified in this study. The suggestion of a symptom response,
together with the lack of dose limiting toxicity provide further support for the continued development of this
product for the treatment of osteoarthritis.
Background
Recent estimates suggest that symptomatic knee osteoar-
thritis (OA) occurs in 13% of persons aged 60 and over
[1,2]. The risk of mobility disability (defined as needing
help walking or climbing stairs) attributable to knee OA
alone is greater than that due to any other medical condi-
tion in people aged 65 and over [3,4]. Current clinical
management for OA is often limited to analgesic
medication and cautious waiting [5] for the sometimes
eventual referral for total joint replacement. There are no
proven therapies that modify the structural changes in
osteoarthritis (OA). Given current clinical need and the
anticipated increase in prevalence, a treatment that pre-
vents OA progression could have a profound effect on
productivity, use of health services and overall quality of
life for persons with OA. A number of different intra-
articular preparations are in development for potential
use in this regard [6-8].
Eptotermin alfa, also called human bone morphoge-
netic protein-7 (BMP-7), was originally isolated from
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in vivo when combined with an appropriate physical
support for matrix cellular attachment.
The recombinant human form of this is referred to as
bone morphogenetic protein 7 (BMP-7). BMP-7 is a
member of the transforming growth factor (TGF)-b
superfamily that contributes to embryonic development
and the repair of mature tissues [9]. BMPs signal via
transmembrane serine/threonine kinase receptors
[10,11]. They can induce a plethora of different cellular
effects ranging from stem cell maintenance, migration,
differentiation, proliferation to apoptosis. The molecular
mechanism, by which the same ligand induces these
manifold effects, depends on the cellular context. It is a
potent bone-inducing molecule that has been used ther-
apeutically to enhance bone formation in spinal fusions
and during fracture repair. In these clinical settings this
product has been generally well tolerated.
BMP-7 has also been shown to have reparative effects
on cartilage. The biological effects of BMP-7 on carti-
lage include stimulation of proteoglycan, collagen and
hyaluronic acid synthesis; induction of receptors, pre-
vention of catabolism of cartilage components by cata-
bolic factors such as interleukin (IL)-1, but no effect on
chondrocyte proliferation and differentiation [12,13].
Compared with normal cartilage, OA cartilage has
decreased levels of BMP-7 [14]. OA cartilage explants
contain up-regulated receptors for BMP-7, and addition
of BMP-7 to human OA cartilage explants results in
anabolic activity by increasing extracellular matrix pro-
duction [15]. Preclinical studies supported this biologic
rationale [16-18].
The primary objective of this Phase 1 study was to deter-
mine the safety and tolerability as well as dose-limiting
toxicity (DLT) and maximal tolerated dose (MTD) of
intra-articular BMP-7.
Secondary objectives were to determine the proportion
of participants with a 20%, 50%, and 70% improvement
in the Western Ontario and McMaster Universities
Osteoarthritis Index (WOMAC) pain and function sub-
scales at 4, 8, 12, and 24 weeks
Methods
This was a double-blind, randomized, placebo-controlled,
single-dose escalation safety study consisting of 4 dosing
cohorts. Each cohort was to consist of 8 treated partici-
pants, with treatment allocation in a 3:1 active to placebo
ratio.
The study was conducted at three sites in the US; 2
sites in Boston, Massachusetts and one in Chapel Hill,
North Carolina. The local Human Research Ethics Com-
mittee at each site approved the study and all partici-
pants provided written informed consent. The study was
prospectively registered with the NIH Clinical Trials
Registry NCT00456157.
Inclusion Criteria
To be eligible for study participation, a patient had to
meet all of the following criteria:
1. Ambulatory persons with OA of the knee with
symptoms for at least 6 months and pain on the major-
ity of days in the last 30 days. In participants with bilat-
eral knee OA, the more symptomatic knee was the
index knee.
2. Age > 40 years
3 .Am i n i m a ls c o r eo f> 8a n d< 1 6o u to f2 0f o rt h e
WOMAC pain subscale in the index knee at the screen-
ing visit after a 2 day NSAID/analgesic washout period.
Participants could take acetaminophen up to 1.0 gram
every 6 hours.
4. Radiographic evidence on PA and lateral standing,
flexed x-rays of at least one osteophyte.
Exclusion Criteria
1. Concurrent medical or arthritic conditions that could
interfere with evaluation of the index knee joint, includ-
ing fibromyalgia.
2. Participant has received arthroscopic or open surgery
to the index joint within 6 months of study start.
3. Corticosteroid, hyaluronic acid or other intraarticu-
lar injection within 3 months of study start.
4. Use of chondroitin and/or glucosamine within 4
weeks of study start.
5. History of Reiter’s syndrome, rheumatoid arthritis,
psoriatic arthritis, ankylosing
spondylitis, lymphoma, arthritis associated with
inflammatory bowel disease, sarcoidosis or amyloidosis.
6. Clinical signs and symptoms of active knee infection
or crystal disease.
7. Clinically significant cardiac disease.
8. Have an increased predisposition for the develop-
ment of infections.
9. History of malignancy, with the exception of
resected basal cell carcinoma, squamous cell carcinoma
of the skin, or resected cervical atypia or carcinoma in
situ.
10. More significant pain from the back or the hip
than the knee.
11. Skin breakdown at the knee where the injection
would take place.
12. Planned knee replacement during the study period.
13. For participants undergo i n gM R I ,t h ep r e s e n c eo f
contraindications to having an MRI at the specific ima-
ging facility.
14. For participants undergo i n gM R I ,t h ep r e s e n c eo f
chronic renal failure defined by a calculated Creatinine
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Gault estimate for GFR as follows: CrCl = (140-age
[yrs]) × weight [kg]/serum creatinine [mg/dL] × 72 with
female gender adjustment (CrCl female = CrCl × 0.85).
15. For participants undergoing MRI, known allergy to
gadolinium contrast material.
16. Having known or clinically suspected infection
with human immunodeficiency virus (HIV), hepatitis C
or B viruses.
17. Having participated within 30 days or will partici-
pate concurrently in another investigational drug or vac-
cine study.
18. Has a history of drug or alcohol dependence in the
past 3 years.
19. Known sensitivity to lidocaine or BMP-7.
20. Female with reproductive capability.
21. Prior use of a bone morphogenetic protein.
Participants who met all of the inclusion criteria and
none of the exclusion criteria were randomized into the
first cohort of 8 participants to receive either 1.0 mL
lactose (placebo) (2 participants) or 1.0 mL containing
0.03 mg of BMP-7(6 participants) intraarticularly in an
outpatient setting on Day 1. Dose selection was based
upon preclinical studies in animals. After an observation
period of at least 1 hour, participants were released and
contacted via telephone on Day 2 to query for adverse
events (AEs) and concomitant medications. Additional
follow-up visits were on Days 7, 14, 28, 56, 84 and 168.
We did not see participants on Day 2 however all parti-
cipants were seen by a physician who performed the
physical examination at each of the listed visits. After
the first and subsequent cohorts of 8 participants each
completed through Day 28, the data were reviewed by
the Safety Committee (an independent monitor, Princi-
pal Investigators from each site and the Study Sponsor)
and when deemed appropriate, the next cohort of 8 par-
ticipants was treated with the next highest dose of
BMP-7. The pre-planned dose escalation was 0.03, 0.1,
0.3 and 1.0 mg BMP-7 intra-articularly. Each cohort was
randomized in a 3:1 treatment-to-lactose (placebo) ratio.
Randomization to lactose (placebo) or study drug was
handled by a call-in randomization process. The investi-
gational pharmacist was unblinded to study drug assign-
ment. Preparation of study drug and lactose (placebo)
occurred in the pharmacies which were then transported
to the treatment area in 3-mL syringes that appeared
identical regardless of whether they contained OP-1 or
lactose (placebo).
Test product, dose and mode of administration
Active Treatment: Recombinant Human BMP-7 (bone
morphogenetic protein -7) was supplied as a lyophilized
cake in 6-mL vials containing 1 mg. Reconstitution with
1.0 mL sterile water for injection (WFI) resulted in a
solution containing 1 mg/mL BMP-7 in 5% lactose
(weight/volume). BMP-7 was diluted as needed per dose
cohort in 5% lactose.
Lactose (placebo) Control: The lactose (placebo) was
provided in a 6-mL vial containing a sterile lyophilized
cake of lactose. It was reconstituted with sterile WFI to
produce a dosage of 5% lactose in 1.0 mL.
Administration: Given under direct ultrasound or
fluoroscopic guidance to ensure injection into the knee
joint.
Handling and preparation of BMP-7 drug product and
lactose (placebo) were carried out by institution staff in
such a way as to maintain study blinding, except that the
study pharmacist was unblinded to each participant’s
study treatment. The institutional pharmacists at each
site had access to a code list identifying whether the par-
ticipant received BMP-7 or lactose (placebo). The phar-
macist did not disclose this information to any study
personnel. BMP-7 was provided in a single dose 6-mL
vial containing a sterile, lyophilized cake of BMP-7.
The participant, study site personnel (other than the
research pharmacist), and Stryker Biotech study staff
were all blinded to the treatment assignments.
Safety Assessment
When a minimum of 4 weeks had elapsed since the last
participant of the current cohort had been treated, all
safety data were collected and reviewed by the safety
committee.
Only after the current dose level had been judged to
be safe were participants enrolled into the next cohort
and dose escalation occurred.
Study sites paid particular heed to the development of
any of the following:
￿ Any evidence of ectopic bone formation not nor-
mally associated with OA.
￿ New or worsening erythema, inflammation and/or
joint swelling of the index knee in the first 14 days
(2 weeks) following study drug injection.
￿ The development of an inflammatory infusion in the
index knee with WBC > 3,000/mm3 and greater than
30% polymorphonuclear leukocytes.
￿ Any serious adverse event thought to be at least pos-
sibly related to study drug
During the screening period lasting 1 to 28 days, par-
ticipants provided medical and arthritis history, includ-
ing the WOMAC questionnaire [19], the KOOS survey
[20], SF-36 [21] and VAS global assessments. The
WOMAC is a disease specific measure that includes
pain (5 items) and physical function (17 items) subscales
that are assessed on a 5-point Likert scale for each. The
OARSI Standing Committee for Clinical Trials Response
Criteria Initiative had developed two sets of responder
criteria to present the results of changes after treatment
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patient’s global assessment) as a single variable for clini-
cal trials with response defined by both a relative and an
absolute change [22].
At each visit concomitant medications were recorded,
physical examination performed, samples obtained for uri-
nalysis, hematology, chemistry, immunology and serum
and plasma banked for biomarker testing. ECG, bilateral
knee x-rays was obtained on all participants and an MRI
of the index knee in selected participants was done.
At each of the study visits, the following clinical
laboratory evaluations were performed:
￿ Hematology: WBC count, RBC count, hemoglobin,
hematocrit, platelet count, WBC differential count.
￿ Coagulation: PT, aPTT, INR
￿ Clinical chemistry: Albumin, alkaline phosphatase,
ALT (SGPT), AST (SGOT), bicarbonate, bilirubin (total),
calcium, phosphorus, chloride, creatinine, glucose, potas-
sium, sodium, total protein, urea (BUN), uric acid.
￿ Urinalysis: Color, appearance, specific gravity, pH,
protein, glucose, ketones, blood, microscopic examina-
tion (RBC, WBC, casts, crystals).
At each visit, patient samples were screened for anti-
BMP 7 IgM and IgG antibodies. Anti- BMP 7 neutraliz-
ing activity was determined only in samples positive for
anti- BMP 7 binding antibodies.
Blood samples for serum were obtained just prior to
injection, immediately post-injection, 1 hour post-injec-
tion and at the 7 day visit to assess BMP 7 drug levels.
Participants were asked to maintain their usual dose of
NSAIDs and/or analgesic during the course of the trial,
except during the 48 hour period preceding KOOS, SF-
36 and patient global assessment evaluations (Acetomi-
nophen was permitted during this 48 hour window).
PA and lateral views of the index knee were taken
serially in follow-up at Days 28, 84 and 168. At the
screening visit, bilateral x-rays were done to determine
presence of osteophytes, to determine study eligibility.
Follow-up x-rays were performed on the index knee
only. X-rays were performed in the 3 recruiting centres
and sent for central reading to a musculoskeletal radiol-
ogist with osteoarthritis expertise.
Participants enrolled at the Boston sites also had an
MRI acquired to assess gadolinium enhanced MRI of
their treated knee for dGEMRIC. MRI results were
exploratory and given concerns over sample size, ade-
q u a t ep o w e r i n ga n da l s ot h ef a c tt h a tw ed i dn o tf i n d
anything (either favourable or adverse) these are not
further presented due to space limitations.
Analysis
The primary objective of this study was to determine the
safety and tolerability including laboratory assessments,
immunogenicity data and radiographic assessments.
All participants receiving any part of at least one injec-
tion of BMP-7 or lactose (placebo) were evaluated for
safety. The safety analyses included evaluation of the inci-
dence of treatment emergent adverse events by preferred
term and body system. Laboratory measures were com-
pared with their corresponding normal ranges, and the
incidence of abnormally high and of abnormally low
laboratory values was calculated for each relevant proto-
col-specified laboratory test. Fixed flexion PA and lateral
x-rays of the index knee for assessment of joint space
narrowing, osteophyte changes and ectopic bone forma-
tion were performed. As this was primarily a safety study
no formal a-priori power calculation was conducted for
secondary endpoints of efficacy.
Secondary objectives were to determine the proportion
of participants with a 20%, 50%, and 70% improvement
in the WOMAC pain and function subscales at 4, 8, 12,
and 24 weeks. Other secondary outcomes included the
change from baseline to 4, 8, 12, and 24 weeks for the
OARSI responder criteria. As this was a Phase 1 study,
descriptive statistics (average, standard deviations, mini-
mum, maximum, proportions, and confidence intervals)
were used to report study data and no formal statistical
techniques have been applied to the data.
Results
The demographic characteristics of the study sample
were broadly consistent between the dosing and placebo
cohorts (Table 1). The total study population had a mean
age of 59.8 years, a mean BMI of 34.2 kg/m
2 and was
73% female. There were no apparent differences in the
cohorts recruited from each site. The mean WOMAC
pain score (possible range 0-20) was 8.6 for the active
treatment groups vs 8.63 for the placebo group. The
mean Kellgren and Lawrence Grade at Baseline was 2.8
in the active group vs 3.4 for the placebo group. The
mean duration of illness for the placebo group was
9.1 years and active 3.9 years.
An additional participant was inadvertently recruited
into the first 0.03 mg cohort as the notification to the
study centers that this cohort was completely recruited
occurred after this participant was screened and enrolled.
M o s ta d v e r s ee v e n t si nt h es t u d yw e r ec a t e g o r i z e da s
mild or moderate and there were no overall differences
in adverse event rates between BMP-7 and placebo
groups (Table 2). Two adverse events were categorized
as severe and unrelated and occurred in the same parti-
cipant (0.03 mg group); acute cholecystitis/cholelithiasis
(requiring surgery) and vaginal hemorrhage (requiring
surgery). There were no life-threatening adverse events
and no deaths in the study. There was more injection
site pain in the 1 mg BMP-7 group and in the analysis
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group. No radiographic abnormalities consistent with
ectopic bone formation were reported in follow-up.
Joint swelling occurred in three participants, all were
classified as mild and all resolved prior to their final
study visit. Two subjects with joint swelling were rando-
mized to the 0.03 dose group, the other to 1.0 mg. Ran-
dom, minor changes in laboratory values occurred
without any apparent trends or clinically significant
abnormalities. No patients developed anti- BMP 7 bind-
ing antibodies during the study. BMP 7 drug levels
results in this study demonstrated that values seen at
1 hr post-dose were very low (near the level of detection
of our PK assay) and sporadic, and had no relationship
to dose group. Most were non-detectable but a few were
near the limit of detection thus not an observable mea-
surement of systemic exposure. There was varied and
sporadic usage of rescue medications throughout the
study without any clear trends or safety concerns identi-
fied. The most common medications administered were
ibuprofen and paracetamol.
By 12 weeks most of the participants in the study
(both BMP-7 and placebo groups) experienced a 20%
improvement in WOMAC pain, and the overall BMP-7
group was similar to placebo (Table 3). In the all
BMP-7 group there was a suggestion of a higher
proportion of response than for the placebo group for
the 50% and 70% reduction endpoints. This trend in the
all BMP-7 group was largely driven by effects seen in
the 0.1 and 0.3 mg dosing cohorts. These dosing cohorts
maintained a trend toward superior 50% improvement
and 70% improvement in pain to week 24. The results
for WOMAC function are generally consistent with
those identified for pain.
The OARSI responder criteria analysis suggested that
t h e r ew e r em o r er e s p o n d e r si nt h eB M P - 7g r o u p st h a n
in the placebo (Table 4). The greatest response was
again seen in the 0.1 and 0.3 mg dosing cohorts.
Discussion
The results of this Phase 1 study are reassuring for
further drug development. There was no dose limiting
toxicity identified in this study overall and no differences
in adverse event rates between BMP-7 and placebo
groups. There was however more injection site pain
reported in the 1 mg BMP-7 group and a less durable
response in pain and function improvement in this speci-
fic group. Importantly there was no evidence of ectopic
bone formation on serial radiographic evaluation.
The trend for BMP-7 symptom response was better than
placebo with the 0.1 and 0.3 mg groups. The bell shaped
dose response curve is consistent with pharmacodynamic
Table 1 Baseline characteristics of study sample. Mean (SD)
0.03 mg
(N = 7)
0.1 mg
(N = 6)
0.3 mg
(N = 6)
1m g
(N = 6)
All
(N = 25)
Placebo
(N = 8)
All Participants
(N = 33)
Age in years 60.1 (11.2) 58.5 (5.3) 62.2 (15.8) 58.5 (5.6) 59.8 (9.9) 59.8 (6.5) 59.8 (9.1)
BMI. kg/m
2 35.7 (8.7) 35.6 (10.9) 33.0 (7.2) 35.8 (8.2) 35.0 (8.3) 31.6 (5.8) 34.2 (7.9)
Gender
(n (%) female)
3 (43%) 6 (100%) 5 (83%) 4 (67%) 18 (72%) 6 (75%) 24 (73%)
Table 2 Adverse events by study group
0.03 mg
(N = 7)
0.1 mg
(N = 6)
0.3 mg
(N = 6)
1m g
(N = 6)
Placebo
(N = 8)
Number of Patients with at least one AE 7 (100%) 5 (83.3%) 5 (83.3%) 6 (100%) 7 (87.5%)
Number of Patients with no AE 0 (0%) 1 (16.7%) 1 (16.7%) 0 (0%) 1 (12.5%)
Arthralagia 4 (57.1%) 1 (16.7%) 5 (83.3%) 5 (83.3%) 6 (75%)
Nasopharyngitis 2 (28.6%) 2 (33.3%) 1 (16.7%) 0 (0%) 1 (12.5%)
Upper Respiratory Tract Infection 1 (14.3%) 0 (0%) 3 (50%) 1 (16.7%) 1 (12.5%)
Headache 1 (14.3%) 2 (33.3%) 2 (33.3%) 0 (0%) 1 (12.5%)
Influenza 0 (0%) 2 (33.3%) 0 (0%) 0 (0%) 2 (25%)
Joint Stiffness 2 (28.6%) 1 (16.7%) 1 (16.7%) 0 (0%) 1 (12.5%)
Joint Swelling 2 (28.6%) 0 (0%) 0 (0%) 1 (16.7%) 0 (0%)
Lymphadenopathy 0 (0%) 1 (16.7%) 0 (0%) 1 (16.7%) 0 (0%)
Injection Site Bruising 0 (0%) 2 (33.3%) 0 (0%) 0 (0%) 0 (0%)
Injection Site Pain 1 (14.3%) 0 (0%) 0 (0%) 4 (66.7%) 1 (12.5%)
Injection Site Mass 0 (0%) 1 (16.7%) 0 (0%) 1 (16.7%) 0 (0%)
Injection Site Swelling 1 (14.3%) 0 (0%) 1 (16.7%) 1 (16.7%) 0 (0%)
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early stage of development the signal identified in this
study is reassuring as similar small trials of intra-articular
therapies for OA (such as IL-1 inhibitors) have not had
similar early phase success to encourage further develop-
ment [6]. Similarly the trends seen in the 1 mg dose group
of increased injection site pain and less apparent efficacy
would suggest this dose not be pursued in further studies.
Preclinical data are roughly equivalent in pattern com-
pared to the reported clinical results; i.e. as expected, there
are low doses that are ineffective, higher doses that scale
to a similar dose in humans that are effective and very
high doses that are either less effective or ineffective.
A non-linear dose response is not atypical with biologic
therapy.
One dose administration was selected as with many
growth factors, there is no clear linkage between the
pharmacodynamic effects of BMP-7 and its temporal
presence in the blood or at the site of action. BMP
dimers bind to specific receptors on the surface of
mesenchymal stem cells and initiate a cascade of events
that eventually leads to the differentiation of new tissues
in the following weeks and months. Preclinical evidence
suggests that a single injection/treatment of BMP-7 is
sufficient to trigger a cascade of bone formation from
months to years.
There are a number of limitations of the current study
that warrant further description. This was primarily a
dose-finding safety study and hence the number of par-
ticipants is small. Any suggestion of efficacy signals for
pain or function need to be adequately determined in
appropriately powered clinical trial/s.
The imaging assessments conducted as part of this
study provided no suggestion of either an adverse safety
profile or hints of efficacy. We do know (via unpub-
lished preclinical data) that there is the potential for dif-
ferentation of stem cells to the osteogenic lineage under
BMP-7 stimulation. The only consistent observation
among the various IA preclinical studies was the spora-
dic formation of small foci (generally no larger than
1-5 mm in diameter) of bone along the needle track
between the skin and the outside of the joint capsule.
Such foci are likely the end result of residual product at
the needle tip. In our human study, the 6 month x-rays
were evaluated for both osteophytes changes and evi-
dence of ectopic bone formation. No patients had any
evidence of ectopic bone formation at six months. To
fully understand the structural effects of BMP-7 admin-
istration in OA will also require adequately powered
clinical trials following participants for 1-2 years.
2 participants were reported to have lymphadenopathy
during follow-up. In preclinical animal models, there is
Table 3 Reduction (improvement) from Baseline in WOMAC Pain. N (%)
0.03 mg
(N = 7)
0.1 mg
(N = 6)
0.3 mg
(N = 6)
1m g
(N = 6)
All
(N = 25)
Placebo
(N = 8)
Mean Baseline Score (0-20) 7.57 10.5 8.2 8.33 8.6 8.6
Week 4 20% Reduction 3 (42.9%) 3 (50.0%) 2 (33.3%) 5 (83.3%) 13 (52%) 1 (12.5%)
Week 8 20% Reduction 3 (42.9%) 5 (83.3%) 3 (50.0%) 5 (83.3%) 16 (64%) 3 (37.5%)
Week 12 20% Reduction 4 (57.1%) 5 (83.3%) 3(50.0%) 1 (16.7%) 13 (52%) 4 (50.0%)
Week 24 20% Reduction 4 (57.1%) 5 (83.3%) 5 (83.3%) 1 (16.7%) 15 (60%) 4 (50.0%)
Week 4 50% Reduction 3 (42.9%) 2 (33.3%) 2 (33.3%) 3 (50.0%) 10 (40%) 0 (0.0%)
Week 8 50% Reduction 1 (14.3%) 3 (50.0%) 3 (50.0%) 4 (66.7%) 11 (44%) 0 (0.0%)
Week 12 50% Reduction 0 (0.0%) 3 (50.0%) 2 (33.3%) 1 (16.7%) 6 (24%) 1(12.5%)
Week 24 50% Reduction 0 (0.0%) 5 (83.3%) 3 (50.0%) 1 (16.7%) 9 (36%) 0 (0.0%)
Week 4 70% Reduction 1 (14.3%) 1 (16.7%) 2 (33.3%) 1 (16.7%) 5 (20%) 0 (0.0%)
Week 8 70% Reduction 1 (14.3%) 1 (16.7%) 2 (33.3%) 1 (16.7%) 5 (20%) 0 (0.0%)
Week 12 70% Reduction 0 (0.0%) 2 (33.3%) 2 (33.3%) 0 (0.0%) 4 (16%) 0 (0.0%)
Week 24 70% Reduction 0 (0.0%) 3 (50.0%) 3 (50.0%) 0 (0.0%) 6 (24%) 0 (0.0%)
Table 4 OARSI responder criteria
Number (%) of Responders 0.03 mg
(N = 7)
0.1 mg
(N = 6)
0.3 mg
(N = 6)
1m g
(N = 6)
All
(N = 25)
Placebo
(N = 8)
Week 4 3 (42.9%) 4 (66.7%) 1 (16.7%) 2 (33.3%) 10 (40%) 1 (12.5%)
Week 8 3 (42.9%) 4 (66.7%) 2 (33.3%) 2 (33.3%) 11 (44%) 0 (0%)
Week 12 1 (14.3%) 4 (66.7%) 2 (33.3%) 1 (16.7%) 8 (32%) 1 (12.5%)
Week 24 1 (14.3%) 5 (83.3%) 2 (33.3%) 1 (20%) 9 (37.5%) 1 (12.5%)
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species at does many fold the dose used in our clinical
trials. Additionally, we see no evidence of meaningful
changes in circulating white blood cell counts.
The success of agents that ultimately seek regulatory
approval for disease modification in OA will be critically
dependent upon the demonstration of symptom
improvement. Consistent with this need BMP-7 appears
to demonstrate an early signal for symptom improvement
that may facilitate seeking a pain indication followed by
structural modification claims.
Conclusions
This trend to a symptom response, together with the lack
of dose limiting toxicity provide further support for the
continued development of this product for treatment of
osteoarthritis. The injection site pain adverse event pro-
file at 1.0 mg coupled with the promising symptom
response will likely see further pursuit of dosing groups
consistent with 0.1 and 0.3 mg dosing cohorts in Phase 2.
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